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Fumiaki Sano,14 Nobuhiko Uoshima,15 Takahiro Yano,16 Yasuhito Nannya,17
Yukiyoshi Moriuchi,18 Ikuo Miura,19 Yoichi Takaue,1 Takahiro Fukuda1The benefits of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myelogenous
leukemia (AML) infirst complete remission (CR1)havemostly beenevaluated inyoungerpatients.Although favor-
ableoutcomesof allo-HCToverchemotherapyhavebeenreportedwith theuseof reduced-intensity conditioning
(RIC) regimens in elderly patients with AML in CR1, information is still limited, especially on the effects of cyto-
genetic risks anddonor sources.Wecollecteddata fromAMLpatients aged50 to70 yearswhoachievedCR1, and
compared theoutcome in152patientswhounderwent allo-HCT inCR1 (HCTgroup) to that in 884patientswho
were treated with chemotherapy (CTx group). The cumulative incidence of relapse in the HCT group was signif-
icantly lower than that in the CTx group (22% versus 62%). Both overall survival (OS) and relapse-free survival
(RFS) were significantly improved in the HCT group (OS: 62% versus 51%, P5 .012), not only in the whole pop-
ulation, but also in the intermediate-risk group.Amongpatientswhohad a suitable related donor, theoutcomes in
theHCT groupwere significantly better than those in theCTx group. The introduction of appropriate treatment
strategies that include allo-HCT may improve the outcome in elderly patients with AML in CR1.
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The biologic characteristics of acute myelogenous
leukemia (AML) change as the patient becomes older,
because suchpatients aremore often associatedwith un-
favorable profiles such as antecedent hematologic disor-
der (AHD), expression of P-glycoprotein in blasts, and
unfavorable-risk cytogenetic abnormalities [1-4]. In
addition, elderly patients are more likely to have
a worse performance status and an increased risk of
comorbidities, which makes it difficult for them
to undergo aggressive therapies [5,6]. Consequently,
the reported probability of achieving a first complete
remission (CR1) is lower than that in younger
patients. In most previous studies, the duration of
remission has been reported to be 6 to 8 months, with
a 3-year survival rate of\20% [7-10].
Although allogeneic hematopoietic cell transplan-
tation (allo-HCT) is an effective strategy for decreasing
the risk of relapse in younger patients, an increase in
the risk of treatment-related toxicity is inevitable. Al-
though .50% of the reported AML patients are 50401
402 Biol Blood Marrow Transplant 17:401-411, 2011S. Kurosawa et al.years of age or older, most previous studies have inves-
tigated treatment strategies that include allo-HCT in
related younger donor/patient pairs by allocating treat-
ment options based on donor availability.Over the past
decade, several studies showed that allo-HCT with
reduced-intensity conditioning (RIC) is acceptably
safe and effective in elderly patients [11-18]. Allo-
HCT with RIC has also been reported to be superior
to conventional chemotherapy in elderly AMLpatients
in CR1, particularly when they have a matched related
donor [19,20].However,most of these studies included
small numbers of patients, and there is still limited
information available on the effects of risk factors of
AML, differences in donor sources, and conditioning
regimens. To address these critical questions, we
performed a nationwide retrospective survey.PATIENTS AND METHODS
Data Source
The study protocol was approved by the institu-
tional reviewboard at theNationalCancerCenterHos-
pital. The targeted population was adult patients who
were diagnosed with AML between 1999 and 2006,
aged 50 to 70 years, and who had achieved CR1 after
1 or 2 courses of induction chemotherapy. The diagno-
sis of AML was determined by theWHO classification
and included myelodysplastic syndrome with 20% or
more bone marrow (BM) blasts. CR was evaluated ac-
cording to standard criteria for hematologic CR, which
was defined as a normocellular BM aspirate containing
5%or less blasts with normalmaturation.The presence
of minimal residual disease was not molecularly exam-
ined in this study. Among them, patients with acute
biphenotypic leukemia who were treated with chemo-
therapy for acute lymphoblastic leukemia, those who
had extramedullary AML without BM invasion or ex-
tramedullary lesion that did not totally disappear after
remission induction chemotherapy, those with acute
promyelocytic leukemia, and those who received autol-
ogous HCT in CR1 were excluded from the analysis.
Information about the disease risks at diagnosis, clinical
course, HLA typing and donor availability duringCR1,
conditioning regimen, and donor source of allo-HCT
were collected. Related donors included an HLA-
matched or 1-antigen (Ag)-mismatched related donor.
A haploidentical related donor who had 2 or more Ag
mismatcheswas considered as an alternativedonor.Un-
related donors included volunteer BM donors with 0 or
1-Ag mismatches and unrelated cord blood with three
or less-Ag mismatches. As HLA typing for unrelated
BM donors was predominantly performed by matches
at serum levels in this era, detailed information on
allele-level matches was not completely available.Statistical Analysis
Datawere retrospectively reviewedandanalyzedasof
December 2009. Background differences between the 2
groups was examined with the chi-square test for cate-
goric variables, and with t-test for metric variables. The
primary endpoints of the study were relapse-free survival
(RFS) and overall survival (OS) from when CR1 was
achieved. The unadjusted probabilities of RFS and OS
were estimated using the Kaplan-Meier product limit
method according to the treatment group, and 95% con-
fidence intervals (CIs) were calculated using the Green-
wood formula. To compare RFS and OS between the
treatment groups, the log-rank test was used. We per-
formed landmark analyses by excluding patients who
died or relapsed within 60 days from CR1 for those
who were treated with chemotherapy alone. Cumulative
incidences were estimated for relapse and nonrelapse
mortality (NRM) to take into account competing risks.
The Pepe andMori’s test was used to evaluate the differ-
ences between groups. RFS, OS, incidences of relapse,
and NRM were estimated as probabilities at 3 years
from CR1. Associations between treatment groups and
outcome were evaluated using Cox proportional hazard
regression models. In addition to whether allo-HCT in
CR1 was performed or not, the following factors were
considered as covariates: cytogenetic classification ac-
cording to the Southwest Oncology Group (SWOG),
FAB classification, the number of courses of chemother-
apy required to achieve CR1, initial white blood cell
(WBC) count, and dysplasia at diagnosis.We considered
2-sidedP-valuesof\.05 tobe statistically significant.Sta-
tistical analyses were performed with the SPSS software
package and SAS version 9.1.3 (SAS, Cary, NC, USA).RESULTS
Patients
Clinical data for around 1300 patients were col-
lected from 67 institutions. After excluding 45 patients
who received autologousHCT inCR1 or other ineligi-
ble patients as described in Patients andMethods, 1036
were eligible for this study (Table 1). The median
follow-up of the surviving patients was 44 months. As
a remission induction therapy, 89% of elderly patients
had received cytarabine- and anthracycline (daunoru-
bicin or idarubicin)-based regimens. Low-dose cyatar-
abine-based regimens were performed in 8% of the
elderly patients. Consolidation therapy was continued
with cytarabine-based regimens with or without main-
tenaice therapy at the discretion of physicians.
Donor Availability and Consideration
of allo-HCT in CR1
Information on HLA typing during CR1 and the
availability of related donors was obtained in 953
Table 1. Patient Characteristics
Characteristics
All Patients
n 5 1036
Allo-HCT in CR1
n 5 152 (%)
No HCT in CR1
n 5 884 (%) P
Median age
years, (range) 60 (50-70) 55 (50-70) 61 (50-70) <.001
Median time from diagnosis to CR1
days, (range) 40 (26-283) 48 (26-242) 39 (13-283) <.001
Disease
M0, 6, 7 102 24 (16) 78 (9) <.001
AHD 37 19 (13) 18 (2) <.001
Cytogenetic risks (SWOG) <.001
Favorable 164 5 (3) 159 (18)
Intermediate 589 93 (61) 496 (56)
Unfavorable 166 27 (18) 139 (16)
Unknown 99 25 (16) 74 (8)
Remission induction 0.13
2 courses 199 36 (24) 163 (18)
WBC (/mL) <.001
Higher than 20,000 335 28 (18) 307 (35)
Dysplasia <.001
Yes 268 74 (49) 194 (22)
Allo-HCT indicates allogeneic hematopoietic cell transplantation; CR1, first complete remission; AHD, antecedent hematologic disorder; WBC, white
blood cell; SWOG, Southwest Oncology Group.
Biol Blood Marrow Transplant 17:401-411, 2011 403Allo-HCT versus CTx for Elderly AML Patients in CR1elderly patients. Among these patients, HLA typing
was performed in 331 patients in CR1 (35%) and these
patients were younger than those who did not have
their HLA typed during CR1 (median, 56 years versus
62 years) (Table 2 and Figure 1). Patients who had
their HLA typed were associated with more unfavor-
able features, such as unfavorable FAB types, AHD,
a requirement of 2 courses of remission induction ther-
apy, dysplasia at diagnosis, and a lower frequency of
favorable-risk AML by the SWOG classification. Re-
lated donors (HLA-matched and 1-Ag-mismatched
related donors) were found in 134 patients (40%).
No significant difference was found in the distribution
of age and risk factors between patients who found a re-Table 2. Donor Search and Transplantation
HLA Che
Characteristics
No HLA
Check in CR1
N 5 622 (%)
Related Donor
Available/HCT+*a
n 5 76 (%)
Related Donor
Available/HCT2
n 5 58 (%)
Age, median, years 62 55 55
Disease
M0, 6, 7 47 (8) 17 (22) 5 (9)
AHD 11 (2) 4 (5) 2 (3)
Cytogenetic risks (SWOG)
Favorable 118 (19) 4 (5) 12 (21)
Intermediate 354 (57) 43 (57) 28 (48)
Unfavorable 92 (15) 13 (17) 9 (16)
Unknown 48 (8) 16 (21) 9 (16)
Remission induction
2 courses 103 (17) 19 (25) 14 (24)
WBC (/mL)
Higher than 20,000 223 (36) 11 (14) 19 (33)
Dysplasia
Yes 127 (20) 31 (41) 16 (28)
CR indicates complete remission; HCT, allogeneic hematopoietic cell transplan
SWOG, Southwest Oncology Group.
*P-value of comparing ‘‘No HLA check in CR1’’ versus ‘‘HLA check in CR1.’’
†P-value of comparing ‘‘Related donor availablea+b’’ versus ‘‘Related donor no
‡P-value of comparing ‘‘HCT+a’’ versus ‘‘HCT-b’’ among those who had a relatlated donor and those who did not after HLA typing
(Table 2). Among the patients who had a related do-
nor, 76 (57%) actually underwent allo-HCT during
CR1. Among the 197 patients who did not find a re-
lated donor, 76 (39%) received allo-HCT from an al-
ternative donor in CR1 (Figure 1).Patients Who Received allo-HCT in CR1
Of the total 1036 patients, 152 underwent allo-
HCT in CR1 (15%). Patients who received allo-HCT
in CR1 were younger and associated with more
unfavorable characteristics than those who did not
(Table 1). As shown in Table 3, 49% of the patientsck in CR1, n 5 331 Statistical Differences
b
Related Donor not
Available/HCT+c
n 576 (%)
Related Donor
not Available/HCT2d
n 5121 (%) P* P† P‡
55 57 <.001 .396 .906
7 (9) 13 (11) 0.008 .170 .160
15 (20) 2 (2) <.001 186 .450
<.001 .561 .045
1 (1) 19 (16)
50 (66) 69 (57)
14 (18) 17 (14)
11 (14) 14 (12)
.009 .541 .871
17 (22) 29 (24)
.021 .178 .004
17 (22) 39 (32)
<.001 .991 .117
43 (57) 26 (21)
tation; AHD, antecedent hematologic disorder; WBC, white blood cell;
t availablec+d’’.
ed donor.
Figure 1. Patient flow. Among 953 patients for whom information was
available, HLA typing was performed in 331 patients in CR1 (35%). Re-
lated donors were found in 134 patients (40%). Among the patients who
had a related donor, 76 (57%) actually underwent allo-HCT in CR1.
Among the 197 patients without a related donor, 76 (39%) received
allo-HCT from an alternative donor in CR1.
404 Biol Blood Marrow Transplant 17:401-411, 2011S. Kurosawa et al.received allo-HCTinCR1 fromanHLA-matched or 1-
Ag-mismatched related donor. The median interval
from CR1 to allo-HCTwas 139 days. An RIC regimen
was given to 93 patients (61%) with a higher median
age of 58 years compared to those who received
a myeloablative (MA) regimen, 52 years. Extensive
chronic graft-versus-host disease (cGVHD) developed
in 61 patients (45%) among 135who lived and had a fol-
low-up period of longer than 100 days.
Comparison of the Outcomes of allo-HCT
versus Chemotherapy in CR1
The outcome in patients who received allo-HCT
in CR1 (HCT group) was compared to that in patients
who did not receive allo-HCT in CR1 (CTx group).
Landmark analyses were performed in all subgroups
by excluding 46 patients from the CTx group who re-
lapsed or died within 60 days after achieving CR1. InTable 3. Characteristics of Transplantation in CR1
Characteristics
Allo HCT in CR1
n 5 152 (%)
Total
Donor
Matched related 64 (42)
1-Ag-mismatched related 10 (7)
Haplo-identical 3 (2)
Unrelated bone marrow 52 (34)
Cord blood 23 (15)
Conditioning
Myeloablative
TBI regimen 16 (11)
Non-TBI regimen 40 (26)
Reduced-intensity
Flu/Bu-based 48 (32)
Flu/Mel-based 29 (19)
Others 16 (11)
Allo-HCT indicates allogeneic hematopoietic cell transplantation; CR, complet
busulfan; Mel, melphalan.the CTx group, 183 patients ultimately received sal-
vage allo-HCTafter relapse (33%of relapsed patients).
The cumulative incidence of relapse in theHCTgroup
was significantly lower than that in the CTx group
(22% versus 62% at 3 years from CR1, P \ .001)
(Figure 2). The cumulative incidence of NRM in the
HCT group was higher than that in the CTx group
(21% versus 3%, P\ .001). The 3-year RFS in the
HCT group was significantly higher than that in the
CTx group (56% versus 29%, P \ .001). Although
the difference between the HCT and CTx groups
decreased, the 3-year OS in the HCT group was also
significantly higher than that in the CTx group (62%
versus 51%, P 5 .012). Multivariate analyses for sur-
vival showed that performance of allo-HCT, a single
course of induction therapy to achieve CR1, lack of
dysplasia, WBC below 20,000/mL at diagnosis, and
a more favorable cytogenetic risk were significantly
associated with better RFS and OS (Table 4). We
also used the Cox proportional hazards model with
time-dependent variables after taking into account
the time from CR1 to allogeneic HCT. By adjusting
the influence of waiting time to allogeneic HCT in
this analysis, we found that allogeneic HCT in CR1
was also independently associated with better OS.
In a subset analysis according to the cytogenetic
risk, patients with intermediate-risk AML showed the
similar trends in relapse, NRM,RFS, andOS to the en-
tire patient population (OS: 67% versus 54%,P5 .024)
(Figure 3A). Among patients with unfavorable-risk
AML, 27 received allo-HCT in CR1 and 125 did not.
In this group of patients, relapse incidence in the
HCT group was also substantial (Figure 3B) (41% at
3 years; 95% CI, 21%-61%), which led to OS that did
not differ significantly compared to that in the CTx
group (OS: 47% versus 35%, P5 .206).
We also evaluated the outcome in relation to
donor availability (Figure 4). Among 134 patientsMedian Age, Years (Range)
Median Interval from CR1
to HCT, Days (Range)
55 (50-70) 139 (14-981)
55 (50-70) 121 (14-574)
57 (50-60) 99 (15-436)
51 (50-54) 144 (21-147)
55 (50-64) 177 (40-981)
55 (50-67) 127 (14-650)
52 (50-58) 167 (52-436)
52 (50-59) 141 (14-361)
58 (50-70) 147 (15-574)
58 (50-66) 126 (14-981)
58 (50-69) 99 (23-304)
e remission; Ag, antigen; TBI, total body irradiation; Flu, fludarabine; Bu,
Figure 2. Outcomes according to treatment in CR1 (total elderly patients). Relapse (upper left), nonrelapse mortality (upper right), relapse-free sur-
vival (bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those
who did not are shown. Forty-six patients who died or relapsed within 60 days from CR1 were excluded as described in the Statistical Analysis. OS was
significantly improved in the HCT group (P 5 .012).
Biol Blood Marrow Transplant 17:401-411, 2011 405Allo-HCT versus CTx for Elderly AML Patients in CR1who had a related donor, 76 underwent allo-HCT in
CR1. The incidence of NRM among the patients
who received allo-HCT from a related donor was
14%, which was significantly lower compared to that
observed in the whole HCT group. On the other
hand, patients who found a related donor but did not
undergo allo-HCT in CR1 had a substantial incidence
of relapse (80%; 95% CI, 70%-90%). These results
led to significant differences in RFS and OS between
the HCT and CTx groups (RFS: 64% versus 11%,
P\ .001, OS: 66% versus 43%, P5 .001) (Figure 4A).Table 4. Multivariate Analysis
RFS
Variables HR (95% CI)
Allo HCT in CR1 (versus Yes)
No 2.58 (1.97-3.37)
Cytogenetic Risk (versus Favorable)
Intermediate 1.14 (0.90-1.44)
Unfavorable 1.70 (1.28-2.24)
Unknown 1.62 (1.18-2.23)
FAB (versus M1, 2, 4, 5)
M0, 6, 7 1.25 (1.00-1.57)
Remission Induction (versus 1 course)
2 courses 1.52 (1.26-1.84)
Dysplasia (versus No)
Yes 1.21 (0.98-1.48)
WBC (versus 20,000 or lower)
Higher than 20,000 1.29 (1.09-1.54)
HR indicates hazard ratio; RFS, relapse-free survival; CI, confidence interval; OS
CR, complete remission; WBC, white blood cell count.These results did not change when 622 patients who
did not have their HLA typed (those who were not
known to have a suitable related donor) were included
in the CTx group (66% versus 54%, P 5 .011)
(Appendix 1-A) or when landmark was extended to 5
months from CR1 for the patients in the CTx group
who had a related donor (66% versus 54%, P 5 .068)
(Appendix 1-B).We also performed the same compari-
son limited to intermediate-risk AMLpatients who had
a related donor, and found significant differences
between the HCT and CTx groups (RFS: 78% versusOS
P HR (95% CI) P
<.001 1.81 (1.35-2.42) <.001
.283 1.10 (0.84-1.45) .487
<.001 1.89 (1.37-2.59) <.001
.003 1.34 (0.92-1.95) .132
.052 1.38 (1.07-1.77) .014
<.001 1.61 (1.31-1.99) <.001
.075 1.29 (1.02-1.63) .033
.004 1.24 (1.01-1.51) .038
, overall survival; allo-HCT, allogeneic hematopoietic cell transplantation;
Figure 3. Outcomes according to treatment in CR1 (cytogenetic risks). Relapse (upper left), nonrelapse mortality (upper right), relapse-free survival
(bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those who
did not are shown among (A) intermediate-risk AML and (B) unfavorable-risk AML. (A) OS was significantly improved in the HCT group among patients
with intermediate-risk AML. (B) Relapse incidence was high even after HCT, and OS in the HCT group did not significantly differ from that in the CTx
group.
406 Biol Blood Marrow Transplant 17:401-411, 2011S. Kurosawa et al.13%, P \ .001, OS: 78% versus 63%, P 5 .048)
(Appendix 1-C).
Among 197 patients who did not have a related
donor, 76 underwent allo-HCT from an alternative
donor inCR1.Alternativedonors included51unrelated
BM, 22 unrelated CB, and 3 haploidentical related
donors. Patients who received allo-HCT in CR1 from
an alternative donor had a higher incidence of NRM
than thosewhoreceivedallo-HCTfroma relateddonor
(28%versus 14% at 3 years,P5 .029). Additionally, in-
cidence of relapse in allo-HCT from an alternative do-
norwas not reduced compared to that in a related donor
transplant setting (22% versus 22%, P5 .743). Conse-
quently, if we compare the outcomes of the HCT and
CTx groups among patients who did not have a related
donor, OS did not significantly differ between the two
groups (57% versus 47%, P5 .388) (Figure 4B).
As shown inTable 3, 39%of thepatients in theHCT
group received an MA regimen. Except for the younger
age in those who received an MA regimen, there was no
difference in the disease risk between the MA and RIC
groups. Additionally, the OS did not significantly differ
between the two groups (3-yearOS fromCR1: 63% ver-
sus 61%, P5 .571) (Appendix 2-A). We also found that
OSwas not significantly different according to the appli-
cation of total body irradiation (TBI) (TBI regimen ver-
sus non-TBI: 67%versus 61%,P5 .932) (Appendix 2-B)
or among different RIC regimens (fludarabine 1
busulfan-based, 56%; fludarabine 1 melphalan-based,
67%; others, 68%, P5 .862) (Appendix 2-C).DISCUSSION
We performed retrospective analyses with a 60-
day landmark to compare allo-HCT and CTx in
1036 patients aged 50 to 70 years with non-M3 AML
in CR1. The results of this study revealed that, overall,
elderly patients with AML who received allo-HCT in
CR1 had improved outcomes compared to those who
were treated with conventional chemotherapy alone.
Based on cytogenetic subgroup analyses, patients
with intermediate-risk AML had a significantly better
OS when they received allo-HCT in CR1. On the
other hand, patients with unfavorable-risk AML had
a higher risk of relapse even after allo-HCT in CR1,
which diminished the benefit of allo-HCT. We also
observed that patients who had a related donor had
a significantly improved outcome when they received
allo-HCT in CR1.
Our results that allo-HCT in CR1 provided an im-
provedOS agree with previously reported comparisons
of allo-HCT versus chemotherapy in elderly patients
with AML inCR1.Mohty et al. [20] performed a retro-
spective comparison of ‘‘donor’’ versus ‘‘no donor’’
based on their consistent policy of considering allo-
HCT with RIC in CR1 when a patient with high-risk
AML had an HLA-matched sibling. They reported su-
perior survival rates not only in the ‘‘transplant group’’
compared to the ‘‘no transplant group,’’ but also in the
‘‘donorgroup’’ compared to the ‘‘nodonorgroup.’’ Fur-
thermore, Estey et al. [19] reported the first prospective
Figure 4. Outcomes according to treatment in CR1 (donor availability). Relapse (upper left), nonrelapse mortality (NRM) (upper right), relapse-free
survival (bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those
who did not are shown among (A) patients who had a suitable related donor and (B) patients who did not have a suitable related donor. (A) NRM was
reduced in related donor transplant and survival probabilities were significantly improved in the HCT group. (B) OS in alternative donor transplant did
not significantly differ from that in the CTx group.
Biol Blood Marrow Transplant 17:401-411, 2011 407Allo-HCT versus CTx for Elderly AML Patients in CR1observation of allo-HCT with RIC versus chemother-
apy in elderly patients. Although the proportions of pa-
tients who were referred for transplantation (54%) and
those who actually underwent allo-HCT inCR1 (14%)
were relatively small, they presented an encouraging
outcome that supported the benefit of allo-HCT.
In elderly patients with intermediate-risk AML, we
also found improved OS when they received allo-
HCT in CR1. This finding is consistent with the result
indicated by a meta-analysis by Koreth et al. [21],
although their report mostly included prospective
studies that targeted younger patients. No previous
studies have reported the effects of cytogenetic risks
in the transplant setting for elderly patients. In the
intermediate-risk group, we found a 60% relapse inci-
dence at 3 years from CR1 when the patients were
treated with chemotherapy alone. We also revealed
that the incidence of relapse was reduced by 40%
with the use of allo-HCT in CR1 without a significant
increase inNRMcompared to younger patients, which
led to a significant improvement of OS.
Our current study did not show a significant benefit
of allo-HCT among patients with unfavorable-risk
AML. Although fewer patients were analyzed in this
subgroup, which may have led to the unlikelihood of
yielding a statistical significance, this result may also
be explained by the fact that elderly patients tend to be
given less-aggressive chemotherapy before allo-HCT
because of concerns about toxicity [7,9]. Because no
other realistic option can offer a chance of cure forpatients with unfavorable-risk AML, many physicians
would consider that allo-HCT is optimal for these pa-
tients. However, we clearly need to seek novel strategies
to reduce the riskof relapse, for example, by reducing the
tumor burden before allo-HCT with more intensified
chemotherapy or conditioning regimen, or by preven-
tion of recurrence after allo-HCT by vaccination strat-
egy [22-27]. The role of new drugs such as clofarabine
or hypomethylating agents should also be estimated
for elderly patients with poor-risk AMLwho are vulner-
able to intensive treatments [28,29].
We observed a markedly reduced incidence of
NRMafter transplantation froma related donor, which
improved the outcome of patients who received allo-
HCT in CR1 from a related donor. Among 134 pa-
tients who had a suitable related donor, 40% did not
undergo allo-HCT during CR1. Unfortunately, the
exact reason was not available from our retrospectively
collected database. Possible reasons include disease
relapse before the anticipated timing for allo-HCT,
or failure to receive appropriate therapy because of
being too ill. However, an analysis with a landmark ex-
tended to 5 months still proved that OS in the HCT
group was significantly better compared to that in the
CTx group among those who had a related donor.
In contrast to the favorable outcome in the setting of
allo-HCT from a related donor, the outcome of allo-
HCT from an alternative donor in CR1 was not signif-
icantly superior to that of chemotherapy alone. In addi-
tion to the significantly higher NRM after alternative
408 Biol Blood Marrow Transplant 17:401-411, 2011S. Kurosawa et al.donor transplant, the incidence of relapse was not re-
duced in the alternative donor transplant compared to
that in related donor transplant despite our expectation
that a graft-versus-leukemia (GVL) effect would be
more potent after allo-HCT from alternative donors.
Several reports have indicated that the outcomes of
allo-HCT from HLA allele-matched unrelated donors
are comparable to those from related donors [14,27].
One possible explanation for this disparity is that
patientswho received allo-HCT from an alternative do-
nor inourdatabasewere significantlymore likely tohave
high-riskAMLthan thosewho received allo-HCTfrom
a related donor. Second, HLA typing was predomi-
nantly performed serologically in the period of our
study. About a third of the patient/donor pairs who are
considered to be matched unrelated pairs by a serologic
examination have been reported to have an allele-
mismatch [30]. In addition, voluntary unrelated donors
consisted only of BM donors because peripheral blood
harvest is not yet allowed in our country, and unrelated
CB accounted for one-third of the alternative donors in
our study. Although allo-HCT from an alternative do-
nor was not shown to have a benefit in elderly patients
in our study, we may expect a better outcome with
a smooth access to an allele-matched unrelated donor.
Whereas prior reports that have compared allo-
HCT and chemotherapy in elderly patients targeted
only allo-HCT with RIC [19,20], one-third of the
HCT group patients in our study received anMA con-
ditioning regimen. However, except for patient age,
there were no significant differences in the disease risks
between the MA and RIC groups, and OS was similar
between the two groups. As has been previously
pointed out, there were no significant differences in
OS among different RIC regimens [31].
Because our database consists of retrospectively
collected clinical data, this cohort of patients may
have several inherent selection biases. Although we
performed a landmark analysis to eliminate the biases
by the patients who did not have a chance to receive
allo-HCT in CR1 because of earlier relapse or comor-
bidity, patients in the HCT group may still have had
favorable features that enabled them to successfully
reach the point of allo-HCT in CR1. Furthermore,
our database did not provide detailed information on
consolidation chemotherapy after achievement of
CR1 or the reasons why patients did not undergo
allo-HCT such as the presence of comorbid condi-
tions. Although the number of the elderly patients
who received autologous HCT in CR1 was small,
the exclusion of these patients may have made the
non-HCT group have even more inherent selection
bias, Nevertheless, the results drawn from our data-
base, which includes 850 patients in the CTx group
and 150 patients in the HCT group, may allow us to
suggest optimal strategies for elderly patients with
AML especially stratified by cytogenetic subgroups.In conclusion, our study indicated that elderly pa-
tients with AML who underwent allo-HCT in CR1
had improved outcomes compared to those who were
treated with conventional chemotherapy alone, and
also revealed that intermediate-risk AML patients had
an improved OS when they underwent allo-HCT in
CR1. Because OS was better in elderly patients when
they have a matched related donor and successfully un-
dergo allo-HCT in CR1, they should be encouraged to
seek the opportunity of allo-HCT in CR1 by perform-
ing HLA typing and donor search in the early period
after achievement of CR1. Novel strategies to reduce
the risk of relapse and better access to allele-matched
unrelated donors should further improve the prognosis
of elderly patients with AML.ACKNOWLEDGMENTS
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Appendix 2. (A)Overall survival (OS) rates fromCR1 are compared betweenmyeloablative and reduced-intensity conditioning regimens. There were
no significant differences between myeloablative and reduced-intensity conditioning regimens (63% versus 61%, P 5 .571). (B) OS did not differ signif-
icantly according to the application of total-body irradiation among patients who received myeloablative regimen (TBI regimen versus non-TBI: 67%
versus 61%, P 5 .932). (C) Among patients who received reduced-intensity conditioning regimen, OS from CR1 did not differ significantly among dif-
ferent regimens (fludarabine 1 busulfan-based, 56%; fludarabine 1 melphalan-based, 67%; others, 68%, P 5 .862).
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